JP2017533945A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533945A5
JP2017533945A5 JP2017526516A JP2017526516A JP2017533945A5 JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5 JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
combination
sulbactam
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533945A (ja
JP6764862B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061076 external-priority patent/WO2016081452A1/en
Publication of JP2017533945A publication Critical patent/JP2017533945A/ja
Publication of JP2017533945A5 publication Critical patent/JP2017533945A5/ja
Application granted granted Critical
Publication of JP6764862B2 publication Critical patent/JP6764862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526516A 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法 Active JP6764862B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17
US62/080,667 2014-11-17
PCT/US2015/061076 WO2016081452A1 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Publications (3)

Publication Number Publication Date
JP2017533945A JP2017533945A (ja) 2017-11-16
JP2017533945A5 true JP2017533945A5 (cg-RX-API-DMAC7.html) 2018-12-20
JP6764862B2 JP6764862B2 (ja) 2020-10-07

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526516A Active JP6764862B2 (ja) 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法

Country Status (31)

Country Link
US (2) US9968593B2 (cg-RX-API-DMAC7.html)
EP (1) EP3221313B1 (cg-RX-API-DMAC7.html)
JP (1) JP6764862B2 (cg-RX-API-DMAC7.html)
KR (1) KR102542392B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108624B (cg-RX-API-DMAC7.html)
AU (1) AU2015350128B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017010132B1 (cg-RX-API-DMAC7.html)
CA (1) CA2966632C (cg-RX-API-DMAC7.html)
CY (1) CY1121384T1 (cg-RX-API-DMAC7.html)
DK (1) DK3221313T3 (cg-RX-API-DMAC7.html)
EA (1) EA033829B1 (cg-RX-API-DMAC7.html)
ES (1) ES2717776T3 (cg-RX-API-DMAC7.html)
HK (1) HK1244798B (cg-RX-API-DMAC7.html)
HR (1) HRP20190580T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044061T2 (cg-RX-API-DMAC7.html)
IL (1) IL251979B (cg-RX-API-DMAC7.html)
LT (1) LT3221313T (cg-RX-API-DMAC7.html)
ME (1) ME03357B (cg-RX-API-DMAC7.html)
MX (1) MX2017006383A (cg-RX-API-DMAC7.html)
MY (1) MY196240A (cg-RX-API-DMAC7.html)
PH (1) PH12017500852B1 (cg-RX-API-DMAC7.html)
PL (1) PL3221313T3 (cg-RX-API-DMAC7.html)
PT (1) PT3221313T (cg-RX-API-DMAC7.html)
RS (1) RS58429B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703633TA (cg-RX-API-DMAC7.html)
SI (1) SI3221313T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900187T1 (cg-RX-API-DMAC7.html)
TR (1) TR201905233T4 (cg-RX-API-DMAC7.html)
TW (1) TWI690317B (cg-RX-API-DMAC7.html)
WO (1) WO2016081452A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703245B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
PT3512851T (pt) * 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA202190617A3 (ru) * 2017-02-08 2021-10-29 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
SMT202200110T1 (it) 2017-05-08 2022-05-12 Entasis Therapeutics Inc Composti e metodi per trattare infezioni batteriche
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
US11660326B2 (en) * 2018-03-13 2023-05-30 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
BR112022018315A2 (pt) * 2020-04-02 2022-10-25 Glaxosmithkline Ip Dev Ltd Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina
CN117062598A (zh) * 2021-01-20 2023-11-14 恩塔西斯治疗有限公司 固定剂量抗生素组合物
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (en) 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
BR112013032770A2 (pt) * 2011-07-26 2017-02-07 Wockhardt Ltd composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
EP2736508A1 (en) 2011-07-26 2014-06-04 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
CA2833241C (en) 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
PT2872510T (pt) 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
US8754102B2 (en) 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) * 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法

Similar Documents

Publication Publication Date Title
JP2017533945A5 (cg-RX-API-DMAC7.html)
PH12017500852B1 (en) Combination therapy for treatment of resistant bacterial infections
WO2018115527A3 (en) Mers coronavirus vaccine
MX2019009443A (es) Metodos para tratar la influenza.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
PH12016501577B1 (en) Monobactam organic compounds for the treatment of bacterial infections
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
ZA202002093B (en) Antibacterial compounds
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
RU2017145271A (ru) Терапевтическое средство для фиброза
PH12018500358A1 (en) Compounds for use in an antibacterial applications
IN2014MU00916A (cg-RX-API-DMAC7.html)
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
MX2017013433A (es) Composiciones antibacterianas.
PH12017502432A1 (en) Compositions and methods for using lamellar bodies for therapeutic purposes
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
EA201890122A1 (ru) Применение 2-(5s-метил-2-оксо-4r-фенилпирролидин-1-ил)ацетамида в лечении судорог
MX379489B (es) Metodos para tratar la osteocondromatosis multiple (mo).
PH12016501215A1 (en) Azaindole derivative
MX376923B (es) Composiciones antibacterianas.